Why Bausch Health Companies Inc. (TSX:BHC) Is a Genius Bet for Long-Term Growth Investors

Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) is a must-own stock for rebound hunters. Here’s why.

| More on:
Pills spilling out of a prescription pot

Image source: Getty Images.

Bausch Health Companies (TSX:BHC)(NYSE:BHC), formerly known as Valeant Pharmaceuticals, has moved on from its troubled past. New CEO Joseph Papa has done an applaud-worthy job of turning the sinking ship that was Valeant into a firm that’s not only capable of surviving, but one that’s poised for a strong return to the growth track. But this time around, it’s all about organic growth, not debt-fueled acquisitive growth with little to no consideration for R&D or solvency.

Simply put, Bausch is an entirely different company than Valeant was before its collapse. It’s a legitimate pharma player with excellent stewardship, terrific assets, and an ambitious turnaround plan.

Most recently, Bausch reached a settlement with generic drug firm Teva Pharmaceuticals that will delay Xifaxan’s generic launch to January 2028. This delay is a big deal for Bausch, as the gastro-focused drug is a crucial pillar of Bausch’s cash flow stream with approximately $1.2 billion in revenues (14% of overall revenues) expected for 2018 to go with robust year-over-year growth moving forward.

David Steinberg, an analyst at Jefferies, believes that the risk of bankruptcy is “off the table” following the settlement. While such commentary from a well-respected analyst is promising, there’s still a considerable amount of debt on the balance sheet that’s still less than ideal, so the company is by no means out of the woods just yet.

The Teva settlement will allow Bausch’s management team more flexibility when it comes to investment in organic growth initiatives, however. A lesser degree of uncertainty with regards to the long-term outlook for Xifaxan’s cash flow stream will allow management to pull different levers to better meet longer-term debt obligations such that the probability of further asset divestments will be lowered substantially.

Foolish takeaway

Sure, Bausch remains highly leveraged, and there’s still a considerable amount of uncertainty with regards to the future success of drugs in the pipeline, but one has to give credit where credit is due. Mr. Papa is a smooth operator, and he’s turned the uninvestable “sinking ship” of a company into one that could realistically surprise and silence all the doubters.

While overall financial wiggle room may be limited compared to the likes of a peer south of the border, I think Mr. Papa’s expertise is well worth the price of admission. He’s a seasoned veteran when it comes to the world of pharma. He knows the ins and outs of the over-the-counter drug business, and I think it’s just a matter of time before he and his team iron out all Bausch’s ugly wrinkles.

A bet on Bausch is a bet on Joseph Papa. At today’s levels, I like that bet.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. The Motley Fool owns shares of Bausch Health Companies.

More on Investing

edit Woman in skates works on laptop
Dividend Stocks

3 No-Brainer Stocks to Buy Under $30

These three stocks all offer a huge deal for investors looking for dividends, as well as growth that will last.

Read more »

Business man on stock market financial trade indicator background.
Tech Stocks

1 Growth Stock Down 50 Percent to Buy Right Now

There are plenty of growth stocks in the market worth considering, but Shopify (TSX:SHOP) looks like one of the best…

Read more »

You Should Know This
Dividend Stocks

How to Convert a $300 Monthly Investment Into $338 in Monthly Income

If you want a certain amount in monthly passive income, invest a similar amount today and leave the rest to…

Read more »

Increasing yield
Dividend Stocks

3 Income Stocks With Big Yields to Consider in April 2024

If you haven’t yet made your March investments, here are three income stocks to buy the dip and lock in…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

RRSP Investors: Don’t Miss Out on This Contribution Hack!

This hack has so many benefits for you -- not just when you put it in your RRSP but for…

Read more »

edit Sale sign, value, discount
Stocks for Beginners

These 3 Growth Stocks Are on Sale and Set to Surge

Some growth stocks are on sale right now that offer massive long-term potential for investors. Here's a trio to consider…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Young woman sat at laptop by a window
Dividend Stocks

3 Dividend Stocks Everyone Should Own for the Long Haul

For investors looking for top-tier dividend stocks to buy and hold for the long term, here are three of my…

Read more »